Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, and Baylor College of Medicine, Houston, Texas.
Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Transfusion. 2019 Apr;59(4):1171-1173. doi: 10.1111/trf.15199. Epub 2019 Feb 14.
KEY IDEAS Chimeric antigen receptor (CAR) T-cell therapy has the potential to improve the dismal outcome of patients diagnosed with acute myeloid leukemia (AML). A major challenge for CAR T-cell therapy of AML patients is identifying leukemia-specific target antigens. Immune escape through down-regulation of target antigens and/or a suppressive tumor microenvironment jeopardizes the success of CAR T-cell therapy.
要点提示 嵌合抗原受体 (CAR) T 细胞疗法有可能改善被诊断患有急性髓系白血病 (AML)的患者的预后。AML 患者 CAR T 细胞疗法的一个主要挑战是确定白血病特异性靶抗原。通过下调靶抗原和/或抑制肿瘤微环境导致免疫逃逸，危及 CAR T 细胞疗法的成功。
